Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 9 (1), 18-27

Current and Emerging Biologics for Ulcerative Colitis

Affiliations
Review

Current and Emerging Biologics for Ulcerative Colitis

Sung Chul Park et al. Gut Liver.

Abstract

Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are be-ing investigated for treating ulcerative colitis. Anti-tumor necrosis factor (TNF) agents were the first biologics to be used for treating inflammatory bowel disease. For example, infliximab and adalimumab, which are anti-TNF agents, are be-ing used for treating ulcerative colitis. Recently, golimumab, another anti-TNF agent, and vedolizumab, an anti-adhesion therapy, have been approved for ulcerative colitis by the U.S. Food and Drug Administration. In addition, new medications such as tofacitinib, a Janus kinase inhibitor, and etrolizumab, another anti-adhesion therapy, are emerging as therapeutic agents. Therefore, there is a need for further studies to select appropriate patient groups for these biologics and to improve the outcomes of ulcerative colitis treatment through appropriate medical usage.

Keywords: Biological therapies; Ulcerative colitis.

Figures

Fig. 1
Fig. 1
Molecular structure of the three tumor necrosis factor antagonists for ulcerative colitis treatment. (A) Infliximab. (B) Adalimumab. (C) Golimumab. Fc, crystalline fragment; Fv, variable fragment; Fcγ1, human immunoglobulin G1 Fc fragment.

Similar articles

See all similar articles

Cited by 22 PubMed Central articles

See all "Cited by" articles

References

    1. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821–826. doi: 10.1016/j.dld.2008.03.014. - DOI - PubMed
    1. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110. doi: 10.1016/j.cgh.2006.09.033. - DOI - PubMed
    1. Stange EF, Travis SP. The European consensus on ulcerative colitis: new horizons? Gut. 2008;57:1029–1031. doi: 10.1136/gut.2007.146761. - DOI - PubMed
    1. Choi CH, Kim YH, Kim YS, et al. Guidelines for the management of ulcerative colitis. Intest Res. 2012;10:1–25. doi: 10.5217/ir.2012.10.1.1. - DOI
    1. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710. doi: 10.1056/NEJMoa1215734. - DOI - PubMed

MeSH terms

Feedback